Masimo (NSDQ:MASI) said today that it won CE Mark approval in the European Union for its MightySat Rx pulse oximeter. The device is designed to noninvasively check oxygen saturation and pulse rate for adults and children during motion and low perfusion, the company said. “Many clinicians around the world rely on pulse oximetry as the 5th […]
Blood Management
Neuravi raises $21m Series B for thrombectomy device
Neuravi said today that it raised $21 million in a Series B round for its Embotrap minimally invasive thrombectomy device. “The intention of the funding round is to launch the device in Europe, to run the Arise program for the U.S., to attempt to bring the device for U.S. approval and to continue to develop further […]
Battelle pairs with Feinstein Institute to develop “neural tourniquet”
Battelle said today that it’s partnering with the Feinstein Institute to develop a novel “neural tourniquet” designed to staunch blood loss using neurostimulation. The device functions by electrically stimulating neural pathways to the spleen, which prepares platelets in the blood for clotting in the event of a wound, Battelle said. Applications anticipated for the device include pre-operative […]
FDA OK doubles Grifols’ plasma production
Grifols profits rise nearly 30%, topping forecasts
Seventh Sense lands $16M for non-invasive blood collection
Massachusetts-based Seventh Sense Biosystems added 3 new investors this month with the closing of its Series B financing round, which brought in $16 million for the the company’s blood sampling devices.
Haemonetics ticks up on fiscal Q1 numbers
Haemonetics (NYSE:HAE) shares ticked up today after the blood management company beat expectations with its fiscal 1st-quarter results.
Podcast: CEO Brian Concannon on the past and future for Haemonetics at MassDevice.com’s DeviceTalks
More than a year ago, Haemonetics (NYSE:HAE) launched a major restructuring effort, moving nearly 300 manufacturing jobs out of the country in an effort to cut between $35 million and $40 million by fiscal 2018.
The cuts were painful, not only for the 42-year-old blood management company and its workers, but for CEO Brian Concannon, who grew up only a stone’s throw from the company’s headquarters in Braintree, Mass.
M&A: Z-Medica nabs TAUREON’S Novacol hemostatic products
Connecticut-based Z-Medical announced this month that it acquired the Novacol resorbable hemostatic product line from rival TAUREON, headquartered in The Netherlands.
TAUREON said that it hopes to focus more on its core businesses, giving over the Novacol line to Z-Medica and its vast distribution network. The companies did not disclose the terms of the deal.
Haemonetics closes Scotland plant, launches $100M buyback after dim quarter
Massachusetts-based Haemonetics (NYSE:HAE) is making some big moves after posting a tough 4th quarter and projecting a dim outlook for the fiscal year ahead.
Haemonetics loses $25M Red Cross deal, shares slide
Haemonetics (NYSE:HAE) said the American Red Cross went with 1 of its rivals for some components of the whole blood collection kits the relief agency uses, meaning a $25 million hit to Haemonetics’ top line.